Daily Endocrinology Research Analysis
Analyzed 35 papers and selected 3 impactful papers.
Summary
Today’s most impactful endocrinology-related papers span mechanistic breakthroughs in cellular metabolism and neuronal energy regulation, and a large-scale clinical cohort linking SGLT2 inhibitors to reduced risk of pyogenic liver abscess in type 2 diabetes. New peroxisome-derived ether lipid control of lysosomal exocytosis and mitochondrial fission factor roles in AgRP neurons redefine metabolic pathophysiology and potential therapeutic targets.
Research Themes
- Mitochondrial dynamics and hypothalamic control of energy homeostasis
- Peroxisome–lysosome lipid signaling in cellular metabolism
- SGLT2 inhibitors and infectious complications risk in type 2 diabetes
Selected Articles
1. Mitochondrial fission factor regulates mitochondrial Ca
Conditional deletion of MFF in AgRP neurons enlarged mitochondria in somata and axons and increased mitochondrial Ca handling, linking mitochondrial dynamics to hypothalamic control of systemic energy homeostasis. This mechanistic work positions MFF-driven fission as a potential target to modulate energy balance.
Impact: Provides in vivo, cell-type specific mechanistic evidence connecting mitochondrial fission to neuronal control of metabolism, with high translational potential for obesity and metabolic disorders.
Clinical Implications: While preclinical, targeting mitochondrial dynamics in hypothalamic AgRP circuits may offer new strategies for anti-obesity therapies. Biomarkers of mitochondrial fission-fusion balance could be explored for patient stratification.
Key Findings
- AgRP neuron-specific MFF loss increased mitochondrial size in soma and axons.
- MFF deficiency led to increased mitochondrial Ca handling in AgRP neurons.
- Findings link mitochondrial fission in AgRP neurons to systemic energy homeostasis.
Methodological Strengths
- Cell-type specific genetic manipulation (AgRP neuron-targeted MFF deletion).
- In vivo assessment across neuronal compartments (somata and axons).
Limitations
- Preclinical mouse study; human translational relevance remains to be established.
- Mechanistic pathways downstream of altered mitochondrial Ca handling were not fully detailed in the abstract.
Future Directions: Define downstream signaling linking altered mitochondrial Ca to AgRP neuronal activity and feeding/energy phenotypes; evaluate pharmacologic modulators of mitochondrial fission in vivo.
Mitochondria represent central regulators of neuronal function, and their network is dynamically restructured via fission and fusion. The mitochondrial fission factor (MFF) serves as an adaptor protein that recruits and organizes the core fission machinery at the outer mitochondrial membrane. Here, we investigated the role of MFF in Agouti-related peptide (AgRP) neurons of the arcuate nucleus of the hypothalamus (ARC) in their regulation of systemic energy homeostasis. We demonstrated that mice lacking MFF in AgRP neurons exhibited increased mitochondrial size, both in AgRP neuron somata and their axonal compartments. This translated into increased mitochondrial Ca
2. Peroxisome-derived ether lipids regulate lysosomal exocytosis.
A genome-wide CRISPR screen uncovered peroxisome-derived ether lipids as bidirectional regulators of lysosomal number and function. Inhibiting ether lipid synthesis enhanced lysosomal exocytosis and degradative clearance independently of TFEB and mannose-6-phosphate trafficking, revealing a peroxisome–lysosome metabolic axis.
Impact: Defines a new lipid-metabolic axis linking peroxisomes to lysosomal homeostasis with strong mechanistic evidence, opening therapeutic avenues for lysosomal/peroxisomal disorders.
Clinical Implications: Findings suggest targets within ether lipid metabolism to modulate lysosomal exocytosis and degradative capacity, with potential relevance to lysosomal storage diseases and metabolic disorders.
Key Findings
- CRISPR screen identified ether lipid synthesis genes/peroxins as modifiers of lysosome accumulation.
- Inhibiting ether lipid synthesis enhanced lysosomal exocytosis and clearance independently of mannose-6-phosphate trafficking and TFEB.
- Hexadecylglycerol supplementation increased lysosome abundance but reduced degradative capacity.
Methodological Strengths
- Unbiased genome-wide CRISPR/Cas9 screen with orthogonal genetic and pharmacologic validation.
- Clear bidirectional perturbations (inhibition vs precursor supplementation) demonstrating causality.
Limitations
- Predominantly cell-based models; in vivo validation and tissue specificity remain to be established.
- Disease relevance inferred; no direct patient data presented.
Future Directions: Test ether-lipid modulation of lysosomal exocytosis in vivo and assess therapeutic potential in lysosomal/peroxisomal disease models.
Lysosomes and peroxisomes are essential for cellular homeostasis, yet how their activities are coordinated remains poorly understood. Here, we identify peroxisome-derived ether lipids as key regulators of lysosomal function. A genome-wide CRISPR/Cas9 screen in LYSET-deficient mucolipidosis V cells revealed that disruption of ether lipid synthesis genes or peroxins markedly reduces lysosome accumulation and restores degradative capacity. Genetic or pharmacological inhibition of ether lipid synthesis enhanced lysosomal exocytosis and promoted the clearance of undigested material independently of mannose-6-phosphate trafficking. Conversely, supplementation with the ether lipid precursor hexadecylglycerol increased lysosome abundance, while reducing their degradative capacity. These findings uncover a peroxisome-lysosome metabolic axis, in which ether lipids act as bidirectional regulators of lysosomal number and function independently of the lysosomal master regulator TFEB. Our findings reveal how peroxisome-localized lipid metabolism modulates lysosomal homeostasis, and suggest potential new strategies to combat lysosomal and peroxisomal disorders.
3. Sodium-glucose cotransporter-2 inhibitors and the risk for liver abscess in patients with type 2 diabetes mellitus: a nationwide retrospective cohort study.
In a propensity score–matched nationwide cohort of 517,600 adults with T2DM, SGLT2 inhibitor use was associated with a lower incidence of pyogenic liver abscess (aHR 0.88; time-dependent aHR 0.72), consistent across subgroups and supported by competing-risks and negative-control analyses.
Impact: Provides robust, population-level evidence that SGLT2 inhibitors may reduce risk of a severe infection (pyogenic liver abscess) in T2DM, informing risk–benefit considerations in clinical prescribing.
Clinical Implications: In T2DM patients, especially in regions with high PLA incidence, SGLT2 inhibitors may confer ancillary infectious risk reduction, potentially influencing agent selection when otherwise clinically appropriate.
Key Findings
- After 1:1 propensity matching (258,800 users vs 258,800 non-users), PLA incidence was 0.75 vs 0.83 per 1,000 person-years.
- Primary model: SGLT2 inhibitor use associated with lower PLA risk (aHR 0.88; 95% CI 0.79–0.99).
- Time-dependent analysis showed stronger association (aHR 0.72; 95% CI 0.64–0.81); results robust across subgroups and sensitivity analyses.
Methodological Strengths
- Nationwide database with very large sample and 1:1 propensity score matching.
- Comprehensive sensitivity analyses including time-dependent Cox, competing-risks, and negative-control outcome.
Limitations
- Retrospective claims-based study susceptible to residual confounding and misclassification.
- Follow-up duration and microbiological confirmation details not reported in the abstract; generalizability outside Taiwan needs evaluation.
Future Directions: Prospective studies to validate causality and explore mechanisms; assess whether risk reduction varies by pathogen profile or concurrent liver disease.
Pyogenic liver abscess (PLA) is a life-threatening infection rising in East Asia, especially among patients with type 2 diabetes. Although SGLT2 inhibitors improve glycemic control and offer extraglycemic benefits, their effect on PLA risk is unknown. Using Taiwan's National Health Insurance Research Database, we conducted a nationwide retrospective cohort study of adults with T2DM. After 1:1 propensity score matching, 258,800 SGLT2i users and 258,800 non-users were included. The primary outcome was incident PLA. Incidence rates were calculated per 1,000 person-years, and adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) were estimated using multivariable Cox proportional hazards models. Additional analyses included subgroup analyses with interaction testing, a time-dependent Cox model, a competing-risks model, and a negative-control outcome analysis using fracture. During follow-up, 1,275 PLA events were identified. The incidence rate of PLA was 0.75 per 1,000 person-years in SGLT2i users and 0.83 per 1,000 person-years in non-users. In the primary multivariable Cox model, SGLT2i use was associated with a lower risk of PLA compared with nonuse (aHR, 0.88; 95% CI, 0.79-0.99). This inverse association was generally consistent across most subgroups. In the time-dependent analysis, SGLT2i use remained associated with a lower PLA risk (aHR, 0.72; 95% CI, 0.64-0.81). SGLT2i therapy was independently associated with reduced PLA risk in T2DM patients, particularly with prolonged exposure. These findings suggest an inverse association between SGLT2i use and the risk of pyogenic liver abscess in patients with T2DM.